BioNTech Completes Minimum Acceptance Criteria for CureVac Share Exchange Offer
ByAinvest
Wednesday, Dec 3, 2025 9:03 am ET1min read
BNTX--
CVAC--
BioNTech has fulfilled the minimum acceptance requirements for the exchange offer for CureVac shares, with 184.071.410 CureVac shares, or 81.74% of the outstanding shares, tendered before the original offer deadline. The offer's acceptance period has begun and will end on December 18, 2025. Non-tendering CureVac shareholders will receive BioNTech ADSs or bar exchange payments after the completion of the post-offer reorganization, which may be subject to Dutch dividend withholding tax.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet